Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer

Ovarian cancer has shown little improvement in survival among advanced-stage patients over the past decade. Current treatment strategies have been largely unsuccessful in treating advanced disease, with many patients experiencing systemic toxicity and drug-resistant metastatic cancer. This study eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Samec, Timothy, Alatise, Kharimat Lora, Boulos, Jessica, Gilmore, Serena, Hazelton, Anthony, Coffin, Carleigh, Alexander-Bryant, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530961/
https://www.ncbi.nlm.nih.gov/pubmed/36213692
http://dx.doi.org/10.1016/j.omtn.2022.09.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530961/
https://www.ncbi.nlm.nih.gov/pubmed/36213692
http://dx.doi.org/10.1016/j.omtn.2022.09.012

Ejemplares similares